Smoldering multiple myeloma (SMM) sits in a gray zone between a benign condition and active cancer. It involves the same type of abnormal cells found in multiple myeloma, a blood cancer, but it hasn’t yet caused any organ damage. Technically, it’s classified as a precursor to cancer, not cancer itself, though the biology is clearly malignant. The distinction matters because it determines whether you need treatment now or careful monitoring over time.
What Smoldering Myeloma Actually Is
Multiple myeloma is a cancer of plasma cells, the white blood cells in your bone marrow that normally produce antibodies. In smoldering myeloma, these plasma cells have already become abnormal and are multiplying more than they should, producing excess antibody protein that shows up in blood tests. But they haven’t yet reached the point where they’re damaging your bones, kidneys, or blood counts.
To be diagnosed with SMM, two things must be true: you have a significant amount of abnormal antibody protein in your blood (at least 3 g/dL) or your bone marrow contains between 10% and 60% abnormal plasma cells, and you have no signs of organ damage. That second criterion is what separates smoldering myeloma from active multiple myeloma. It’s the difference between cells that are behaving abnormally and cells that are actively causing harm.
How It Differs From Active Myeloma
Active multiple myeloma is defined by a set of problems known by the acronym CRAB: high calcium levels in the blood, renal (kidney) failure, anemia, and bone lesions. These are signs that the abnormal plasma cells have grown aggressive enough to damage organs and bones. If any of these are present, the diagnosis shifts from smoldering to active myeloma, and treatment typically begins.
In 2014, the International Myeloma Working Group expanded the definition of active myeloma to capture patients who hadn’t developed CRAB symptoms yet but were almost certain to progress very quickly. If your bone marrow contains 60% or more abnormal plasma cells, or if the ratio of involved to uninvolved antibody light chains in your blood exceeds 100, or if an MRI shows more than one focal lesion, you’re now reclassified as having active myeloma regardless of symptoms. These thresholds were added because patients meeting them had a 72% to 95% chance of progressing within two years. In practice, this means the highest-risk patients who would have once been labeled “smoldering” are now treated as active cancer.
The Risk of Progression
Not everyone with smoldering myeloma will develop active cancer. About 30% of patients progress within five years, and roughly 44% progress within ten years. The annual risk runs about 6.8% per year for the first five years, then drops to around 2.9% per year over the following five. Some people live with SMM for decades without ever needing treatment.
The variation in outcomes is enormous, which is why doctors put significant effort into figuring out where you fall on the risk spectrum. A widely used tool called the 20/2/20 model looks at three numbers: whether your bone marrow plasma cells exceed 20%, whether your free light chain ratio exceeds 20, and whether your M-protein level exceeds 2 g/dL. Having none of these risk factors puts you in a low-risk category. One factor means intermediate risk. Two or more means high risk, with a much faster expected timeline to progression.
Monitoring Instead of Treatment
For most people with smoldering myeloma, the standard approach is active surveillance rather than treatment. This means regular blood tests, urine tests, and imaging to watch for any signs that the disease is progressing toward active myeloma. The typical schedule starts with a follow-up about three months after your initial diagnosis. If results are stable, visits shift to every four to six months for the first year, then every six to twelve months after that. Annual MRI scans are generally recommended for at least five years to check for bone changes that might not cause symptoms yet.
This “watch and wait” approach can feel unsettling. Many people struggle with knowing they have abnormal cells multiplying in their bone marrow while their doctor recommends doing nothing. But for low-risk and many intermediate-risk patients, the evidence consistently shows that early treatment doesn’t improve outcomes compared to waiting until the disease actually progresses. The drugs used to treat myeloma carry real side effects, and exposing someone to those side effects years before they need treatment doesn’t extend their life.
When Treatment Starts Earlier
High-risk smoldering myeloma is where the conversation changes. Clinical trials are actively testing whether early treatment for high-risk patients can delay or even prevent progression to active myeloma. Some of these trials have shown promising results, and certain cancer centers now offer early intervention for patients whose lab values and risk profiles suggest they’re likely to progress within a few years.
The shift toward treating high-risk SMM reflects a broader change in how oncologists think about the condition. Rather than a single diagnosis, smoldering myeloma is increasingly understood as a spectrum. At one end are patients with mildly abnormal lab values who may never need treatment. At the other end are patients whose disease is biologically almost indistinguishable from active myeloma, separated only by the fact that organ damage hasn’t shown up yet on tests. For that second group, waiting for damage to occur before starting treatment may not be the best strategy.
So Is It Cancer?
The most accurate answer is that smoldering myeloma is a clonal plasma cell disorder with malignant potential. The cells are abnormal in the same way cancer cells are. They carry many of the same genetic mutations found in active myeloma. But the disease hasn’t crossed the threshold into causing the kind of damage that defines cancer in a clinical sense. Most oncologists describe it as a precancerous or premalignant condition, similar to how certain types of precancerous polyps in the colon aren’t colon cancer but involve abnormal cells that could become cancer.
What this means for you practically: if you’ve been diagnosed with SMM, you don’t have active cancer that needs immediate treatment in most cases. But you do have a condition that requires consistent monitoring because it carries a real and measurable risk of becoming active myeloma over time. Your specific risk depends heavily on your individual lab values and how they fit into established risk models, which is why the numbers from your blood work and bone marrow biopsy matter so much in shaping your follow-up plan.